MA46341A - Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 - Google Patents

Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5

Info

Publication number
MA46341A
MA46341A MA046341A MA46341A MA46341A MA 46341 A MA46341 A MA 46341A MA 046341 A MA046341 A MA 046341A MA 46341 A MA46341 A MA 46341A MA 46341 A MA46341 A MA 46341A
Authority
MA
Morocco
Prior art keywords
monocyclic
cyclic
new
bicyclic system
prmt5 inhibitors
Prior art date
Application number
MA046341A
Other languages
English (en)
Inventor
Lijs Beke
An Boeckx
Dirk Brehmer
Gaston Stanislas Marcella Diels
Edward Charles Lawson
Lieven Meerpoel
Vineet Pande
Marcus Cornelis Bernardus Catharina Paradé
Wim Bert Griet Schepens
Weimei Sun
Johannes Wilhelmus John F Thuring
Marcel Viellevoye
Tongfei Wu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA46341A publication Critical patent/MA46341A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
MA046341A 2016-10-03 2017-10-02 Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 MA46341A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662403336P 2016-10-03 2016-10-03
EP17157785 2017-02-24

Publications (1)

Publication Number Publication Date
MA46341A true MA46341A (fr) 2019-08-07

Family

ID=60043171

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046341A MA46341A (fr) 2016-10-03 2017-10-02 Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5

Country Status (15)

Country Link
US (3) US11098062B2 (fr)
EP (1) EP3519413A1 (fr)
JP (2) JP7101171B2 (fr)
KR (1) KR102531344B1 (fr)
CN (2) CN109803971B (fr)
AU (1) AU2017338269B2 (fr)
BR (1) BR112019006414A2 (fr)
CA (1) CA3037998A1 (fr)
IL (1) IL265718B (fr)
MA (1) MA46341A (fr)
MX (2) MX2019003843A (fr)
PE (1) PE20190706A1 (fr)
PH (1) PH12019500731A1 (fr)
TN (1) TN2019000087A1 (fr)
UA (1) UA124074C2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202321249A (zh) * 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
CA3084449A1 (fr) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Nouveaux analogues spirobicycliques
WO2019219805A1 (fr) * 2018-05-16 2019-11-21 Ctxone Pty Ltd Polythérapie
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
CN113186153B (zh) * 2021-04-15 2023-09-08 南方医科大学 Prmt5抑制剂在促进精原干细胞损伤再生和增殖中的应用
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
WO2003039523A2 (fr) 2001-11-05 2003-05-15 Exiqon A/S Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
IL163613A0 (en) 2002-02-19 2005-12-18 Cv Therapeutics Inc Partial and full agonists of a1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
WO2005005450A1 (fr) 2003-07-15 2005-01-20 Mitsui Chemicals, Inc. Procede de synthese d'un bisdinucleoside cyclique
JP2007537999A (ja) 2003-12-19 2007-12-27 コローニス ファーマシューティカルズ インコーポレイテッド 変異原性複素環
EP1844062A2 (fr) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibiteurs d'adn-methyltransferase
JP2009542608A (ja) 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
WO2010039548A2 (fr) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Modifications chimiques de monomères et d’oligonucléotides par cycloaddition
EP2513298A4 (fr) 2009-12-18 2013-03-27 Harvard College Composés promouvant la réplication des cellules bêta et méthodes d'utilisation de ces composés
WO2012075500A2 (fr) 2010-12-03 2012-06-07 Epizyme, Inc. Modulateurs à base de 7-déazapurine de l'histone méthyltransférase et procédés d'utilisation de ceux-ci
EP2646455A4 (fr) 2010-12-03 2014-04-02 Epizyme Inc Modulateurs d'histone méthyltransférase et leurs procédés d'utilisation
CA2819894A1 (fr) 2010-12-16 2012-06-21 Abbvie Inc. Composes antiviraux
EP2694524B1 (fr) 2011-04-04 2016-05-18 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Dérivés de 2'-o-aminooxyméthyl nucléoside pour l'utilisation dans la synthèse et la modification de nucléosides, nucléotides et oligonucléotides
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
WO2014035140A2 (fr) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
UA118548C2 (uk) 2012-12-21 2019-02-11 Епізайм, Інк. Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP2935240A1 (fr) 2012-12-21 2015-10-28 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
US10087151B2 (en) 2014-01-09 2018-10-02 The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
EP3160477A4 (fr) 2014-06-25 2018-07-04 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
CN106999479B (zh) 2014-07-01 2021-07-16 米伦纽姆医药公司 可用作sumo活化酶抑制剂的杂芳基化合物
JP6584521B2 (ja) 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
CN108884108B (zh) 2016-03-10 2021-08-31 詹森药业有限公司 用于用作prmt5抑制剂的取代核苷类似物
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用

Also Published As

Publication number Publication date
IL265718B (en) 2021-08-31
AU2017338269B2 (en) 2021-03-25
CN109803971A (zh) 2019-05-24
PE20190706A1 (es) 2019-05-17
MX2019003843A (es) 2019-06-24
JP2019534255A (ja) 2019-11-28
KR20190056425A (ko) 2019-05-24
PH12019500731A1 (en) 2019-06-24
TN2019000087A1 (en) 2020-07-15
BR112019006414A2 (pt) 2019-06-25
US11098062B2 (en) 2021-08-24
JP2022084699A (ja) 2022-06-07
KR102531344B1 (ko) 2023-05-10
CN109803971B (zh) 2022-10-28
IL265718A (en) 2019-05-30
CN115626935A (zh) 2023-01-20
JP7101171B2 (ja) 2022-07-14
US20210371433A1 (en) 2021-12-02
EP3519413A1 (fr) 2019-08-07
US20240124493A1 (en) 2024-04-18
US20190263833A1 (en) 2019-08-29
AU2017338269A1 (en) 2019-04-04
CA3037998A1 (fr) 2018-04-12
UA124074C2 (uk) 2021-07-14
MX2023005574A (es) 2023-05-29

Similar Documents

Publication Publication Date Title
MA46341A (fr) Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
DK3812900T3 (da) Systemer, fremgangsmåder og apparater til heterogen beregning
DK3607984T3 (da) Fremgangsmåde til generering af en aerosoltåge
MA42032A (fr) Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
IT201700070755A1 (it) “sistema di separazione”
FR3033919B1 (fr) Procede de generation d'une sequence video cyclique
FR3037401B1 (fr) Caracterisation d'un echantillon par decomposition en base de materiaux.
MA41542A (fr) Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase
DK3256690T3 (da) Brøndboringsindsprøjtningssystem
IT201700112144A1 (it) Sistema di oscillazione per sedie
FR3031502B1 (fr) Ensemble de pointage d'un instrument
IT201600128143A1 (it) Sistema di guida simultanea
FR3057578B1 (fr) Procede d'hydrodesulfuration d'une essence olefinique.
FR3046749B1 (fr) Systeme de gonflage-degonflage d'un pneumatique
FR3039966B1 (fr) Dispositif de formation d'un andain
EA201691833A1 (ru) Уличный столб
IT201700035964A1 (it) “divisorio per boiserie”
DK3482908T3 (da) Uv-bestrålingsanordning; indretning til termoformning; samt fremgangsmåde til at fremstille en formdel
IT201600106709A1 (it) Procedimento per la preparazione di un’ammina solforata
FR3055928B1 (fr) Systeme de desolidarisation en rotation d'arbres
IT201900000499U1 (it) Sistema parapetto
DK3844260T3 (da) Mikrofluidsystemer til gærældningsanalyse